Cargando…

RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment

PURPOSE: Sorafenib is an oral multikinase inhibitor with regulatory approval in advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and refractory differentiated thyroid carcinoma (DTC). Vascular endothelial growth factor receptor (VEGFR) inhibitors like sorafenib may cause proteinur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oya, Mototsugu, Kaneko, Shuichi, Imai, Tsuneo, Tsujino, Toshiaki, Sunaya, Toshiyuki, Okayama, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135823/ https://www.ncbi.nlm.nih.gov/pubmed/35445315 http://dx.doi.org/10.1007/s00280-022-04428-0

Ejemplares similares

A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance
por: Akaza, Hideyuki, et al.
Publicado: (2015)

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
por: Kaneko, Shuichi, et al.
Publicado: (2016)

Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006)

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
por: Procopio, G, et al.
Publicado: (2013)

RETRACTED ARTICLE: Thyroid nodules update in diagnosis and management
por: Tamhane, Shrikant, et al.
Publicado: (2015)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells
por: Suzuki, Kenjiro, et al.
Publicado: (2013)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
por: Tomita, Yoshihiko, et al.
Publicado: (2021)

Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents
por: Uemura, Hirotsugu, et al.
Publicado: (2021)

Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
por: Tomita, Yoshihiko, et al.
Publicado: (2021)

Retraction of articles
Publicado: (2012)

Retraction of articles
Publicado: (2011)

Retraction of articles
Publicado: (2010)

Retraction of articles
Publicado: (2012)

Retraction of articles
Publicado: (2011)

Articles retraction
Publicado: (2018)

RETRACTED ARTICLE: FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism
por: Qiao, Yujie, et al.
Publicado: (2019)

Renal angiomyolipoma: a radiological classification and update on recent developments in diagnosis and management
por: Jinzaki, Masahiro, et al.
Publicado: (2014)

Article Retraction Notice
Publicado: (2019)

Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma
por: Zustovich, Fable, et al.
Publicado: (2011)

Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
por: Ye, Ding-Wei, et al.
Publicado: (2014)

Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma
por: Zhang, Yushi, et al.
Publicado: (2015)

Sorafenib improves the postoperative effect of early stage renal cell carcinoma
por: Liu, Taiyang, et al.
Publicado: (2016)

Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer
por: Qiu, Juhui, et al.
Publicado: (2019)

Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma
por: Lamarca, A, et al.
Publicado: (2012)

Retracted Article: Ligustrazine attenuates renal damage by inhibiting endoplasmic reticulum stress in diabetic nephropathy by inactivating MAPK pathways
por: Yang, Hongling, et al.
Publicado: (2018)

Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report
por: Imai, Tsuneo, et al.
Publicado: (2022)

Protocol to screen for Sorafenib resistance regulators using pooled lentiviral shRNA library and a Sorafenib-resistant hepatocellular carcinoma cell model
por: Gao, Ruize, et al.
Publicado: (2023)

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
por: Zhang, Liang, et al.
Publicado: (2011)

Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma
por: Sil, Amrita, et al.
Publicado: (2014)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma
por: Kasahara, Ryo, et al.
Publicado: (2017)

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)

Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS
por: Ikeda, Takanori, et al.
Publicado: (2021)

Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub‐analysis from the XAPASS study
por: Ikeda, Takanori, et al.
Publicado: (2022)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4bg2blinmjnerr9efav1c7f8fa